Is Eppendorf profitable in 2025?

Yes but thinly. Eppendorf's EBIT margin collapsed from 18.3% in 2022 to 4.0% in FY2024 (€39.4M EBIT on €980.3M revenue), and FY2025 revenue fell further to €924M. The company remains profitable but margins have nearly disappeared over three years.

Could AI replace Eppendorf's products?

No. Eppendorf makes physical instruments (pipettes, centrifuges, consumables) requiring GLP/GMP-certified manufacturing and precision engineering, none of which AI can substitute. Its VisioNize Lab Suite software remains rules-based device monitoring, not AI-driven, per current product documentation as of 2026.

Who is Eppendorf's biggest competitor?

Thermo Fisher Scientific is the most direct threat: it opened a new pipette-tip Manufacturing Center of Excellence producing 40 million tips per week in August 2025, aimed squarely at Eppendorf's consumables core business. Sartorius, Gilson, and INTEGRA Biosciences also compete in liquid handling.

Eppendorf SE (formerly Eppendorf AG) is a private company headquartered in Hamburg, Germany, not exchange-listed for trading. GlobalData and BCC Research classify it as privately held as of July 2026; no current public ownership-structure disclosure was found.

Is Eppendorf laying off workers?

Yes, gradually. Headcount dropped from 5,571 in 2023 to 5,093 in 2024 (-9.0%) and to 4,948 in 2025 (-2.9%), per Revelio Labs data from June 2026. Part of this reflects a July 2025 divestiture of Thailand operations to DKSH Management.

Has Eppendorf launched any AI features?

No evidence found. Eppendorf's VisioNize Lab Suite remains a cloud-based rules-based device monitoring platform (alerts, audit trail), not an AI or LLM-driven system, based on its own product documentation as of the most recent search.

Biotech tools companies · Germany

Eppendorf AG

eppendorf.com ↗

German maker of lab pipettes, centrifuges, and consumables for research labs.

Protection under test

Assessed 24 July 2026 · Evidence as of 24 July 2026

Something worth protecting exists and is being tested right now.

On the recordSince 24 July 2026 · Checkable from H1 2026 · Every call on the record Checkpoint: Full FY2025 annual report with detailed EBIT margin and segment breakdown

The call

Eppendorf still holds certifications, tip lock-in, and a global service network, but three straight years of falling revenue and margin overlap with Thermo Fisher's new consumables capacity coming online.

Eppendorf makes pipette tips, centrifuges, and other tools for laboratories and pharmaceutical factories. Its brand name and certifications give it real advantages that are hard to copy, but its sales have dropped sharply since 2022, and Thermo Fisher is now building massive factories to make cheap pipette tips and directly compete with Eppendorf's core business. The question is whether Eppendorf's decline is a temporary slump from the end of the COVID boom that it can recover from, or whether it is losing permanent market share to a much larger competitor, which would be much harder to fix.

Why

AI pressure: None apparent. No AI lab-agent or model is displacing pipettes and centrifuges yet; the risk is Eppendorf's own VisioNize software falling behind on AI features. Could AI do the core job? Unlikely.

Bigger players: Thermo Fisher Scientific. Thermo Fisher opened a 40 million tips per week plant in August 2025, aimed straight at Eppendorf's core consumables business. Could a giant copy it? Yes, easily.

What protects it. GLP/GMP certifications, tip geometry that locks customers into Eppendorf-specific pipettes, and a service network in 30+ countries.

What would change this call

Eppendorf FY2026 revenue growth or decline versus FY2025's €924M. Shows whether the 2022-2025 revenue slide is bottoming out or continuing structurally.
Thermo Fisher quarterly reports showing consumables/tips volume growth through 2026-2027. Would indicate Thermo's new capacity is visibly taking pipette-tip share from Eppendorf.
Eppendorf FY2026 EBIT margin versus FY2025's 4.0%. Tests whether profitability stabilizes or approaches zero, signaling deeper structural trouble.

Key numbers

Revenue fell from €1.23B (2022) to €924M (2025)
EBIT margin dropped from 10.8% to 4.0% (2024)
R&D spend cut from €76M to €60.9M (2025)

Named risks

Three straight years of revenue decline (EUR 1.23B to 924M) with EBIT margin collapsing to 4.0% by FY2024. Severity: high
Thermo Fisher's 40M tips/week capacity (Aug 2025) directly targets Eppendorf's consumables moat. Severity: high
Continued headcount reduction, down about 11% from 2023 to 2025. Severity: medium
No AI-driven feature shipped on VisioNize while competitors emphasize AI-driven lab platforms. Severity: medium
Ownership structure and governance details remain unverified in public sources. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Thermo Fisher Scientific	gaining on	Opened 40M tips/week manufacturing center August 2025 targeting Eppendorf's consumables core
Sartorius AG	contesting	Overlapping bioprocess and liquid-handling consumables lines, direct German rival
Gilson Inc.	contesting	Long-standing direct competitor in manual and electronic pipetting
INTEGRA Biosciences and Corning	contesting	Compete on pipette tips and liquid-handling consumables per 2026-05 market report

Questions people ask

Is Eppendorf profitable in 2025?: Yes but thinly. Eppendorf's EBIT margin collapsed from 18.3% in 2022 to 4.0% in FY2024 (€39.4M EBIT on €980.3M revenue), and FY2025 revenue fell further to €924M. The company remains profitable but margins have nearly disappeared over three years.
Could AI replace Eppendorf's products?: No. Eppendorf makes physical instruments (pipettes, centrifuges, consumables) requiring GLP/GMP-certified manufacturing and precision engineering, none of which AI can substitute. Its VisioNize Lab Suite software remains rules-based device monitoring, not AI-driven, per current product documentation as of 2026.
Who is Eppendorf's biggest competitor?: Thermo Fisher Scientific is the most direct threat: it opened a new pipette-tip Manufacturing Center of Excellence producing 40 million tips per week in August 2025, aimed squarely at Eppendorf's consumables core business. Sartorius, Gilson, and INTEGRA Biosciences also compete in liquid handling.
Who owns Eppendorf?: Eppendorf SE (formerly Eppendorf AG) is a private company headquartered in Hamburg, Germany, not exchange-listed for trading. GlobalData and BCC Research classify it as privately held as of July 2026; no current public ownership-structure disclosure was found.
Is Eppendorf laying off workers?: Yes, gradually. Headcount dropped from 5,571 in 2023 to 5,093 in 2024 (-9.0%) and to 4,948 in 2025 (-2.9%), per Revelio Labs data from June 2026. Part of this reflects a July 2025 divestiture of Thailand operations to DKSH Management.
Has Eppendorf launched any AI features?: No evidence found. Eppendorf's VisioNize Lab Suite remains a cloud-based rules-based device monitoring platform (alerts, audit trail), not an AI or LLM-driven system, based on its own product documentation as of the most recent search.

Timeline

2026-03Launched SpinPro 6 R refrigerated centrifuge series with RFID rotors and CO2 cooling
2025-09Launched Research 3 neo manual pipette line with sustainability ACT label
2025-08Thermo Fisher opened 40 million tips/week pipette-tip manufacturing center, direct threat to Eppendorf
2025-07-21Divested direct Thailand operations to DKSH Management, kept exclusive distribution rights
2024-10-01Dr. Christine Munz became Group CEO, succeeding Dr. Wilhelm Pluster
2024-04Hans-Christian Stuff became CFO
2023FY2023 revenue fell to EUR 1.0782 billion, down about 12.6% from 2022
2020-03-19Acquired Koki Holdings centrifuge business including himac brand

Revision history

24 July 2026

First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.

In the same band

Bio-Rad Laboratories Olympus Corporation Catalent, Inc.